不明原因不孕的医学辅助生殖或期待治疗的成本效果:何时开始治疗?
该研究用决策分析Markov模型模拟女性年龄<38岁的不明原因不孕夫妇3年内五种治疗顺序策略,以活产概率、治疗与分娩费用、多胎妊娠概率、ICER和净收益为结局。若一次活产价值≤€32 000,2年期待管理后行IVF最具成本效果;若>€32 000,则为1年期待管理、1年IUI-OS后行IVF。
要点
- 女性<38岁不明原因不孕,2年期待管理后IVF在活产价值≤€32 000时最具成本效果。
- 活产价值>€32 000时,1年期待管理+1年IUI-OS+1年IVF更具成本效果。
- IVF-EM-EM和EM-IVF-EM被EM-EM-IVF支配,IUIOS-IVF-EM被EM-IUIOS-IVF支配。
核心结论
- EM-EM-IVF和EM-IUIOS-IVF后行IVF是最具成本效果的策略,选择取决于对一次活产赋予的货币价值。
研究设计与样本
- 决策分析Markov模型,随访女性年龄<38岁的不明原因不孕夫妇自 Fertility workup 完成后3年,时间轴分为三个1年周期。
- 模型基于当代证据,自然妊娠动态预测模型结合网络Meta分析中RCT的MAR治疗效果。
- 共比较五种治疗策略:IVF-EM-EM、EM-IVF-EM、EM-EM-IVF、IUIOS-IVF-EM和EM-IUIOS-IVF。
- 采用荷兰社会视角,对第2和第3年应用标准贴现程序,概率敏感性分析重复20 000次。
主要发现
- 从IVF-EM-EM到EM-IUIOS-IVF,活产概率约54-64%,平均费用约€4000至€9000。
- EM-EM-IVF支配IVF-EM-EM和EM-IVF-EM,EM-IUIOS-IVF支配IUIOS-IVF-EM。
- 去除被支配策略后,EM-IUIOS-IVF相比EM-EM-IVF的ICER约为€31 000。
- 净收益曲线显示:活产价值约≤€20 000时EM-EM-IVF净收益最高概率最大;€20 000至€50 000之间不确定,转折点€32 000;>€50 000时EM-IUIOS-IVF净收益最高概率最大。
- 不同基线预后亚组显示相同的被支配策略和相同的两种最可能净收益最高的策略,但活产货币价值阈值不同。
关键数值与推荐
- 若一次活产价值≤€32 000,2年期待管理后IVF最具成本效果。
- 若一次活产价值>€32 000,1年期待管理、1年IUI-OS后1年IVF最具成本效果。
- ICER for EM-IUIOS-IVF compared to EM-EM-IVF approximately €31 000.
临床怎么用
- 结果可用于临床医生、夫妇和政策制定者讨论,基于活产概率、费用和MAR治疗局限性决定可持续治疗方案。
- 选择治疗策略时应考虑对一次活产赋予的货币价值阈值。
局限性
- 模型聚焦人群水平,基于平均周期数的平均费用。
- 模型基于多项关键假设,改变假设评估其影响;IVF相对效果随时间变化对结果及解读影响很大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Over a time period of 3 years, which order of expectant management (EM), IUI with ovarian stimulation (IUI-OS) and IVF is the most cost-effective for couples with unexplained subfertility with the female age below 38 years? SUMMARY ANSWER: If a live birth is considered worth €32 000 or less, 2 years of EM followed by IVF was the most cost-effective, whereas above €32 000 this was 1 year of EM, 1 year of IUI-OS and then 1 year of IVF. WHAT IS KNOWN ALREADY: IUI-OS and IVF are commonly used fertility treatments for unexplained subfertility although many couples can conceive naturally, as no identifiable barrier to conception could be found by definition. Few countries have guidelines on when to proceed with medically assisted reproduction (MAR), mostly based on the expected probability of live birth after treatment, but there is a lack of evidence to support the strategies proposed by these guidelines. The increased uptake of IUI-OS and IVF over the past decades and costs related to reimbursement of these treatments are pressing concerns to health service providers. For MAR to remain affordable, sustainable and a responsible use of public funds, guidance is needed on the cost-effectiveness of treatment strategies for unexplained subfertility, including EM. STUDY DESIGN, SIZE, DURATION: We developed a decision analytic Markov model that follows couples with unexplained subfertility of which the woman is under 38 years of age for a time period of 3 years from completion of the fertility workup onwards. We divided the time axis of 3 years into three separate periods, each comprising 1 year. The model was based on contemporary evidence, most notably the dynamic prediction model for natural conception, which was combined with MAR treatment effects from a network meta-analysis on randomized controlled trials. We changed the order of options for managing unexplained subfertility for the 1 year periods to yield five different treatment policies in total: IVF-EM-EM (immediate IVF), EM-IVF-EM (delayed IVF), EM-EM-IVF (postponed IVF), IUIOS-IVF-EM (immediate IUI-OS) and EM-IUIOS-IVF (delayed IUI-OS). PARTICIPANTS/MATERIALS, SETTING, METHODS: The main outcomes per policy over the 3-year period were the probability of live birth, the average treatment and delivery costs, the probability of multiple pregnancy, the incremental cost-effectiveness ratio (ICER) and finally, which policy yields the highest net benefit in which costs for a policy were deducted from the health effects, i.e. live births gained. We chose the Dutch societal perspective, but the model can be easily modified for other locations or other perspectives. The probability of live birth after EM was taken from the dynamic prediction model for natural conception and updated for Years 2 and 3. The relative effects of IUI-OS and IVF in terms of odds ratios, taken from the network meta-analysis, were applied to the probability of live birth after EM. We applied standard discounting procedures for economic analyses for Years 2 and 3. The uncertainty around effectiveness, costs and other parameters was assessed by probabilistic sensitivity analysis in which we drew values from distributions and repeated this procedure 20 000 times. In addition, we changed model assumptions to assess their influence on our results. MAIN RESULTS AND THE ROLE OF CHANCE: From IVF-EM-EM to EM-IUIOS-IVF, the probability of live birth varied from approximately 54-64% and the average costs from approximately €4000 to €9000. The policies IVF-EM-EM and EM-IVF-EM were dominated by EM-EM-IVF as the latter yielded a higher cumulative probability of live birth at a lower cost. The policy IUIOS-IVF-EM was dominated by EM-IUIOS-IVF as the latter yielded a higher cumulative probability of live birth at a lower cost. After removal of policies that were dominated, the ICER for EM-IUIOS-IVF was approximately €31 000 compared to EM-EM-IVF. The range of ICER values between the lowest 25% and highest 75% of simulation replications was broad. The net benefit curve showed that when we assume a live birth to be worth approximately €20 000 or less, the policy EM-EM-IVF had the highest probability to achieve the highest net benefit. Between €20 000 and €50 000 monetary value per live birth, it was uncertain whether EM-EM-IVF was better than EM-IUIOS-IVF, with the turning point of €32 000. When we assume a monetary value per live birth over €50 000, the policy with the highest probability to achieve the highest net benefit was EM-IUIOS-IVF. Results for subgroups with different baseline prognoses showed the same policies dominated and the same two policies that were the most likely to achieve the highest net benefit but at different threshold values for the assumed monetary value per live birth. LIMITATIONS, REASONS FOR CAUTION: Our model focused on population level and was thus based on average costs for the average number of cycles conducted. We also based the model on a number of key assumptions. We changed model assumptions to assess the influence of these assumptions on our results. The change in relative effectiveness of IVF over time was found to be highly influential on results and their interpretation. WIDER IMPLICATIONS OF THE FINDINGS: EM-EM-IVF and EM-IUIOS-IVF followed by IVF were the most cost-effective policies. The choice depends on the monetary value assigned to a live birth. The results of our study can be used in discussions between clinicians, couples and policy makers to decide on a sustainable treatment protocol based on the probability of live birth, the costs and the limitations of MAR treatment. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the ZonMw Doelmatigheidsonderzoek (80-85200-98-91072). The funder had no role in the design, conduct or reporting of this work. B.W.M. is supported by a NHMRC Practitioner Fellowship (GNT1082548). B.W.M. reports consultancy for ObsEva, Merck KGaA and Guerbet and travel and research support from ObsEva, Merck and Guerbet. TRIAL REGISTRATION NUMBER: N/A.
引用
- van Eekelen R, Eijkemans MJ, Mochtar M, et al. Cost-effectiveness of medically assisted reproduction or expectant management for unexplained subfertility: when to start treatment? Hum Reprod. 2020. PMID: 32876323. doi:10.1093/humrep/deaa158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。